enGene Holdings Inc. (ENGN)
Market Cap | 397.05M |
Revenue (ttm) | n/a |
Net Income (ttm) | -115.28M |
Shares Out | 44.17M |
EPS (ttm) | -148.05 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 76,890 |
Open | 9.26 |
Previous Close | 9.05 |
Day's Range | 8.73 - 9.51 |
52-Week Range | 6.69 - 47.17 |
Beta | -0.64 |
Analysts | Strong Buy |
Price Target | 34.40 (+282.65%) |
Earnings Date | Jun 14, 2024 |
About ENGN
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ENGN stock is "Strong Buy." The 12-month stock price forecast is $34.4, which is an increase of 282.65% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/v/5/press10-2479471.jpg)
enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-...
![](https://cdn.snapi.dev/images/v1/d/k/conf5-2451268.jpg)
enGene to Present at the Jefferies Global Healthcare Conference
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal stud...
![](https://cdn.snapi.dev/images/v1/p/y/press6-2433364.jpg)
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal stud...
![](https://cdn.snapi.dev/images/v1/z/n/conf19-2407521.jpg)
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting
Oral presentation highlights rational design of EG-70 to address challenges faced by other intravesical treatment options, including preparation, handling, and safety considerations BOSTON and MONTREA...
![](https://cdn.snapi.dev/images/v1/m/y/press2-2363053.jpg)
/C O R R E C T I O N -- enGene Inc./
In the news release, engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development, issued 09-Apr-2024 by enGene Inc., the headline was incorrectly tr...
![](https://cdn.snapi.dev/images/v1/p/r/press18-2363900.jpg)
enGene Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development
BOSTON and MONTREAL , April 9, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead produ...
![](https://cdn.snapi.dev/images/v1/x/d/press5-2318853.jpg)
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress
Pivotal phase 2 LEGEND study of EG-70 in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) remains on track with interim data anticipated in mid-2024 Closed a $200 million oversubscribed pri...
![](https://cdn.snapi.dev/images/v1/7/q/conf15-2308105.jpg)
enGene To Present at the Leerink Partners Global Biopharma Conference
BOSTON and MONTREAL , March 5, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN) or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is i...
![](https://cdn.snapi.dev/images/v1/j/r/press12-2275307.jpg)
enGene Announces Oversubscribed $200 Million Private Placement Financing
Financing included participation from new and existing investors Pro forma cash and cash equivalents expected to fund current operating plan into 2027 BOSTON and MONTREAL , Feb. 14, 2024 /PRNewswire/ ...
![](https://cdn.snapi.dev/images/v1/2/s/press2-2275298.jpg)
enGene Announces Leadership Succession Plan
BOSTON and MONTREAL , Feb. 14, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN) ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in ...
![](https://cdn.snapi.dev/images/v1/g/7/press17-2250307.jpg)
enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary
Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support enGene during late-stage clinical development and anticipated future commercial ...
![](https://cdn.snapi.dev/images/v1/f/i/press7-2248399.jpg)
enGene Reports Full Year 2023 Financial Results and Recent Operational Progress
Achieved primary and secondary endpoints in Phase 1 portion of LEGEND study in non-muscle invasive bladder cancer (NIMBC); pivotal portion underway with interim data expected mid this year Completed a...
![](https://cdn.snapi.dev/images/v1/d/y/press14-2207015.jpg)
enGene Announces Expanded $50 Million Debt Facility with Hercules Capital
BOSTON and MONTREAL , Dec. 22, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene," Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead EG-70 program is in a pivotal study for BCG-unre...
![](https://cdn.snapi.dev/images/v1/c/2/press15-2201543.jpg)
enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors
BOSTON and MONTREAL , Dec. 19, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene," Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsi...
![](https://cdn.snapi.dev/images/v1/w/8/press18-2175510.jpg)
enGene Appoints Ryan Daws as Chief Financial Officer
BOSTON and MONTREAL , Nov. 29, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene,") (NASDAQ: ENGN) (NASDAQ: ENGNW), a clinical-stage genetic medicines company whose lead program is in a pivotal study ...
![](https://cdn.snapi.dev/images/v1/p/r/press19-1848410-2137719.jpg)
Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company
CAD$191 million gross proceeds from the transaction to support the advancement of the clinical program and pipeline expansion. Pivotal clinical trial for lead program EG-70 targeting BCG-unresponsive ...
![](https://cdn.snapi.dev/images/v1/b/e/press10-2132554.jpg)
enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company
Business combination transaction completed with Forbion European Acquisition Corp. Clinical stage biotechnology company with EG-70 lead program in pivotal clinical study targeting BCG-unresponsive non...